

PBG S.A.

HOLD reiterated. Risk rating downgraded to Medium.

Recommendation and forecast revision. Introduction of 2011E.

We fine tune our 2009E/2010E EPS estimates on the back of new Management guidance, acquisition of significant material contracts and 1Q09 figures. At the same time we introduce 2011E figures. We reiterate both 12M Target Price of PLN 220 and recommendation to Hold the stock, though we revise up the risk rating from Low to Medium on the back of dilution risk. Though we still find business model and underlying market fundamentals as healthy and offering good growth prospects, we recognize the announced new share issues as accounting for additional dilution risk for current shareholders.

Solid 1Q09 Results – Above consensus

PBG reported 1Q09 net profit of PLN 23.2m (+57% yoy) that is 21% above consensus and 25% above our estimate. The operating profit of PLN 34.8m (+16% yoy) has beaten our and consensus estimates by 11%. General impression – good set of operating results, at the net level additionally supported by low tax rate in the group (positive tax at Hydrobudowa).

Management Guidance for 2009

PBG issued its 2009 guidance with targeted top line of PLN 2,800m, EBIT of PLN 300m and net profit of PLN 190m. The guidance does not include any proceeds from Armenian projects due to the uncertainty of its execution. Our forecast comes close to the guidance though we apply slightly different breakdown of the segments in the top line as we expect larger share of oil and gas and specialized construction on the back of successful acquisition of Euro 2012 stadium contracts and different FX rates assumptions.

High share capital increase considered. Risk increases.

The rapid expansion of PBG group to new market segments was fuelled by acquisitions financed in part by new shares issuances in the past. Currently PBG considers launching new segment involved in energy segment through acquisition of an incumbent and considers issuance of 0.86m shares, 4m of convertible bonds and 2.7m of shares, the latter subject to Board decision. This would imply dilution in the range between 27% and 36%, while the return on new capital remains unknown as long as PBG does not reveal its acquisition target.

Table 1 Summary Financial Data

| | 2006 | 2007 | 2008 | 2009E | 2010E | 2011E |
|--------------------|-------|---------|---------|---------|---------|---------|
| Revenues (PLN m) | 674.3 | 1 407.0 | 2 091.4 | 2 711.8 | 3 205.0 | 3 463.6 |
| EBITDA (PLN m) | 88.4 | 166.1 | 271.5 | 351.1 | 424.9 | 451.4 |
| EBIT (PLN m) | 70.6 | 167.5 | 227.9 | 299.9 | 366.1 | 389.5 |
| Net profit (PLN m) | 52.2 | 104.3 | 158.2 | 201.4 | 254.2 | 270.0 |
| EPS (PLN) | 4.63 | 8.19 | 11.78 | 15.00 | 18.93 | 20.11 |
| DPS (PLN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EV/EBITDA | 35.3 | 24.2 | 11.5 | 9.7 | 7.8 | 6.8 |
| P/E (x) | 55.5 | 37.5 | 16.6 | 13.9 | 11.0 | 10.4 |


Source: Company, IPOPEMA Research

13 May 2009

PBG

HOLD – Medium Risk

12M TP PLN 220 / (May 12th) PLN 208.3



| Key Ratios | 2009E | 2010E |
|--------------------|-------|-------|
| EBITDA Margin | 12.9% | 13.3% |
| EBIT Margin | 11.1% | 11.4% |
| ROE | 18.1% | 18.0% |
| Bank Debt / Assets | 28.0% | 21.9% |

Share data

| | |
|---------------------------------|---------------|
| Number of shares (m) | 13.4 |
| Market Cap (€m) | 635.8 |
| 12M Avg daily volume (th) | 30.2 |
| 12M Average daily turnover (€m) | 2.49 |
| 52 W High / Low | 318.5 / 175.3 |
| WIG Weight (%) | 1.64 |
| Reuters | PBGG.WA |
| Bloomberg | PBG PW |

| Performance | Abs. | vs. WIG |
|-------------|------|---------|
| 3M | 2% | -16% |
| YTD | 4% | -5% |
| 12M | -34% | 6% |

Shareholders

| Shareholders | Stake |
|----------------------------|-------|
| Wiśniew ski Jerzy | 50.1% |
| BZ WBK AIB Investment Fund | 5.1% |
| ING NN Pension Fund | 5.1% |
| Other | 39.7% |

Analysts

| | |
|--------------------------------|-------------------|
| Arkadiusz Chojnacki, CFA | + 48 22 236 92 44 |
| arkadiusz.chojnacki@ipopema.pl | |
| Tomasz Duda | + 48 22 236 92 32 |
| tomasz.duda@ipopema.pl | |

Forecasts Revision

We fine tune our 2009E/2010E EPS estimates on the back of new Management guidance, acquisition of significant material contracts and 1Q09 figures. At the same time we introduce 2011E figures. We recognize new accounting rules applies by PBG to recognition of consortium partners' sales, greater risk of Armenian contract, the volatility of FX rates and the recently signed, large stadium contracts.

PBG. 2009E-10E Forecasts Revision. Introduction of 2011E. (PLN m)

| | 2009E | | | 2010E | | | 2011E |
|----------------------|----------------|----------------|------------|----------------|----------------|------------|----------------|
| | Old | New | chg | Old | New | chg | New |
| Revenues | 2 618.4 | 2 711.8 | 4% | 3 291.5 | 3 205.0 | -3% | 3 463.6 |
| Gross Profit | 432.3 | 426.6 | -1% | 550.5 | 509.3 | -7% | 551.2 |
| gross margin | 16.5% | 15.7% | | 16.7% | 15.9% | | 15.9% |
| SG&A cost | -123.1 | -127.5 | 4% | -148.1 | -144.2 | -3% | -162.8 |
| SG&A as % of sales | -4.3% | -4.7% | | -4.9% | -4.5% | | -4.7% |
| EBIT | 321.0 | 299.9 | -7% | 403.4 | 366.1 | -9% | 389.5 |
| Net Income | 201.2 | 201.4 | 0% | 258.8 | 254.2 | -2% | 270.0 |
| EPS (PLN) | 15.0 | 15.0 | 0% | 19.3 | 18.9 | -2% | 20.1 |

Source: IPOPEMA Research

PBG issued its 2009 guidance with targeted top line of PLN 2,800m, EBIT of PLN 300m and net profit of PLN 190m. Our forecast comes close to the guidance though we apply slightly different breakdown of the segments in the top line as we expect larger share of oil and gas and specialized construction on the back of successful acquisition of Euro 2012 stadium contracts and different FX rates assumptions. At the same time we expect the robust growth of water segment to be less spectacular in the forthcoming years, the conclusion supported by backlog figures of water segment. The water segment backlog at the end of 2007 stood at PLN 2.2 bn, while after 1Q09 we estimate the figure at PLN 1.8-1.9 bn as the backlog of Hydrobudowa Polska of PLN 2.3 bn included already Baltic Arena. We still believe the prospects of the water market in Poland are robust, though we apply conservative approach on the back of PBG's policy of selection of the most profitable contracts, which might turn in lower acquisition ratio at current construction market.

Comparison of 2009 PBG guidance and Ipopema estimates. (PLN m)

| 2009 figures | Ipopema | PBG guidance | Diff |
|--------------|---------|--------------|-------|
| Revenues | 2 711.8 | 2 800.0 | -3.1% |
| EBIT | 299.9 | 300.0 | 0.0% |
| Net profit | 201.4 | 190.0 | 6.0% |

Source: IPOPEMA Research

High share capital increase considered. Risk increases.

The rapid expansion of PBG group to new market segments was fuelled by acquisitions financed in part by new shares issuances in the past. Currently PBG considers launching new segment involved in energy segment through acquisition of an incumbent and considers issuance of 0.86m shares, 4m of convertible bonds and 2.7m of shares, the latter subject to Board decision. This would imply dilution in the range between 27% and 36%, while the return on new capital remains unknown as long as PBG does not reveal its acquisition target. Due to increased dilution risk we find the premium on PBG no longer justified.

| Company | Last Price | Market Cap (PLN m) | 2009E | 2010E | 2011E | 2009E | 2010E | 2011E |
|---------------|------------|--------------------|-------------|-------------|-------------|------------|------------|------------|
| | | | P/E | | | EV/EBITDA | | |
| Budimex | PLN 73.5 | 1 889 | 14.5 | 13.0 | 11.7 | 8.9 | 7.5 | 6.3 |
| Elektrobudowa | PLN 150 | 695 | 13.6 | 12.9 | 12.9 | 9.1 | 8.3 | 7.7 |
| Erbud | PLN 37 | 463 | 11.9 | 12.9 | 11.1 | 8.7 | 8.4 | 7.3 |
| PBG | PLN 208.3 | 2 717 | 14.1 | 11.0 | 10.9 | 9.5 | 7.5 | 7.2 |
| Polimex | PLN 3.75 | 1 588 | 14.4 | 14.2 | 11.3 | 7.7 | 7.2 | 6.1 |
| MEDIAN | | | 14.1 | 12.9 | 11.3 | 8.9 | 7.5 | 7.2 |

Source: IPOPEMA Research

Financials

| P&L (PLN m) | 2006 | 2007 | 2008 | 2009E | 2010E | 2011E |
|---|--------------|--------------|--------------|--------------|--------------|--------------|
| Revenues | 674 | 1 407 | 2 091 | 2 712 | 3 205 | 3 464 |
| - <i>yoj change</i> | 65% | 109% | 49% | 30% | 18% | 8% |
| Gross Profit | 116 | 215 | 342 | 427 | 509 | 551 |
| - <i>yoj change</i> | 63% | 85% | 59% | 25% | 19% | 8% |
| Other Operating Income/(Cost) | 10 | 6 | -8 | 1 | 1 | 1 |
| EBIT | 71 | 168 | 228 | 300 | 366 | 389 |
| - <i>yoj change</i> | 45% | 137% | 36% | 32% | 22% | 6% |
| EBITDA | 88 | 166 | 272 | 351 | 425 | 451 |
| - <i>yoj change</i> | 76% | 88% | 64% | 29% | 21% | 6% |
| Financial Income/(Cost) | -1 | -21 | -12 | -12 | -12 | 11 |
| Other and Extraordinary | | | | | | |
| Pretax Profit | 70 | 146 | 216 | 288 | 354 | 401 |
| Income Tax | -15 | -27 | -26 | -46 | -60 | -68 |
| Minority (Profits)/Losses | -3 | -15 | -32 | -41 | -40 | -63 |
| Net Income | 52 | 104 | 158 | 201 | 254 | 270 |
| EPS (PLN) | 4.63 | 8.19 | 11.78 | 15.00 | 18.93 | 20.11 |
| - <i>yoj change</i> | 24% | 77% | 44% | 27% | 26% | 6% |
| Profitability Ratios | | | | | | |
| Gross Margin | 17.2% | 15.3% | 16.3% | 15.7% | 15.9% | 15.9% |
| EBIT Margin | 10.5% | 11.9% | 10.9% | 11.1% | 11.4% | 11.2% |
| Net Margin | 7.7% | 7.4% | 7.6% | 7.4% | 7.9% | 7.8% |
| ROE | 28.3% | 27.5% | 20.2% | 18.1% | 19.3% | 17.2% |
| Balance Sheet (PLN m) | | | | | | |
| Total Current Assets | 592 | 1 425 | 1 822 | 2 116 | 2 276 | 2 355 |
| Cash and Equivalents | 51 | 410 | 290 | 298 | 288 | 277 |
| Other Current Assets | 541 | 1014 | 1533 | 1817 | 1987 | 2078 |
| Total Fixed Assets | 343 | 587 | 775 | 859 | 913 | 920 |
| Tangible Assets | 266 | 307 | 427 | 513 | 568 | 577 |
| Other Fixed Assets | 77 | 281 | 347 | 346 | 345 | 343 |
| Total Assets | 1 045 | 2 259 | 2 859 | 3 288 | 3 523 | 3 604 |
| Stockholders` Equity | 379 | 785 | 1114 | 1315 | 1569 | 1839 |
| Including Minority Interest | 12 | 35 | 185 | 185 | 185 | 185 |
| Long Term Liabilities | 213 | 332 | 410 | 459 | 391 | 363 |
| Long -Term Debt | 70 | 50 | 113 | 153 | 103 | 67 |
| Other Long - Term liabilities | 142 | 282 | 297 | 306 | 287 | 296 |
| Short Term Liabilities | 453 | 1142 | 1335 | 1515 | 1563 | 1401 |
| Short - Term Debt | 205 | 467 | 671 | 770 | 682 | 477 |
| Other Current Liabilities | 248 | 675 | 663 | 745 | 881 | 924 |
| Total Equity & Liabilities | 1 045 | 2 259 | 2 859 | 3 288 | 3 523 | 3 604 |
| BVPS (PLN) | 30.5 | 55.9 | 69.1 | 84.1 | 103.0 | 123.1 |
| Balance Sheet Ratios | | | | | | |
| Current Ratio | 1.6 | 1.5 | 1.6 | 1.6 | 1.7 | 2.0 |
| Quick Ratio | 0.1 | 0.4 | 0.2 | 0.2 | 0.2 | 0.2 |
| Bank Debt/Assets | 26% | 23% | 27% | 28% | 22% | 15% |
| Bank Debt/Equity | 73% | 66% | 70% | 70% | 50% | 30% |
| Cash Flow (PLN m) | | | | | | |
| Net Profit | 52 | 104 | 158 | 201 | 254 | 270 |
| Depreciation and Amortisation | 16 | 27 | 46 | 51 | 59 | 62 |
| Other (incl. WC) | -203 | -249 | -467 | -246 | -74 | -33 |
| Operating Cash Flows | -134 | -118 | -263 | 6 | 239 | 299 |
| Capital Expenditures (Net) | -153 | -188 | 0 | -136 | -112 | -69 |
| Other | 41 | 9 | 0 | 0 | 0 | 0 |
| Cash Flows from Investing Activities | -112 | -179 | 0 | -136 | -112 | -69 |
| Change in Debt | 46 | 342 | 0 | 138 | -137 | -241 |
| Issuance of Shares | 187 | 333 | 0 | 0 | 0 | 0 |
| Other | -16 | -20 | 0 | 0 | 0 | 0 |
| Cash Flows from Financing Activities | 217 | 655 | 0 | 138 | -137 | -241 |
| Beginning Cash | 82 | 51 | 410 | 149 | 158 | 148 |
| Increase/(Decrease) in Cash | -30 | 359 | -263 | 9 | -10 | -11 |
| Ending Cash | 51 | 410 | 149 | 158 | 148 | 137 |
| DPS (PLN) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |

Source: IPOPEMA Research

This document has been prepared by:

IPOPEMA Securities S.A.
ul. Walićów 11
00-851 Warszawa
www.ipopema.pl

IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (*Komisja Nadzoru Finansowego*).

This document is intended for IPOPEMA Securities S.A. clients, yet it may be sent to the mass media. Its copying or publishing in whole or in part as well as dissemination of information enclosed to it is allowed only with prior written permission of IPOPEMA Securities S.A. It was prepared by its authors to provide background information only and it is based on publicly available information viewed as reliable. It has been produced independently of the company mentioned in this report and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise stated, sources of all information in charts and tables are IPOPEMA Securities S.A. estimates.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness, reliability and attention on the basis of publicly available information, which IPOPEMA Securities S.A. believes to be reliable. While all reasonable care and diligence has been taken to ensure that the facts stated herein are accurate and that any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the company, IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. This document has been furnished solely for your information and may not be reproduced or redistributed to any other person. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada or Japan.

This document does not constitute or form part of any offer for sale or solicitation of any offer to buy any shares nor shall it or any part of it form the basis or be relied on in connection with any contract or commitment whatsoever. Investment decisions should be made only on the basis of the prospectus or other publicly available documents and materials.

Investors should be aware that IPOPEMA Securities S.A. may have a conflict of interest that could affect this report's objectivity. IPOPEMA Securities S.A. may seek to do business with the companies mentioned in this document.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the reports author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could result in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This report was not transferred to the company prior to its publication.

Recommendations issued by IPOPEMA Securities S.A. are valid for twelve months or unless it is updated. The updates to the recommendation will be provided based on the analyst's judgment and there is no predefined frequency of issuance of such publications

The date stated on the front page is the date of the publication of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this report.

The definitions of terms used in the recommendation include:

NII – Net interest income – interest income minus interest expense
Net F&C – Net fee and commission income – fee and commission income minus fee and commission expense
LLP – loan loss provisions – an expense set aside as an allowance for bad loans
NPL – non-performing loan – loans that are in default or close to be in default
Cost/Income – operating expenses divided by total banking revenue
ROE – return on equity – net income (or adjusted net income) divided by the average shareholders' equity
ROA – return on assets – net income (or adjusted net income) divided by the average assets
EBIT – interests before earnings and tax
EBITDA – interest before earnings, tax, depreciation and amortization
EPS – earnings per share – the net income (or adjusted net income) divided by the number of shares outstanding
P/E – price to earnings ratio – price divided by earnings per share
PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time
CAGR – compound annual growth rate
BVPS – book value per share, the book value of the Company's equity divided by the number of shares outstanding
P/BV – price to book value - price divided by the BVPS
DPS – dividend per share – dividend of a given year divided by the number of shares outstanding
DY – dividend yield – dividend of a given year divided by the current price
DDM – dividend discount model – a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends
TP – target price, calculated based on valuation methods outlined in the document

Our recommendations are:

Buy – expected 12 months total return of 15% or more.

Hold – expected 12 months total return of 5%-15%.

Sell – expected 12 months total return of below 5%.

There are three risk ratings: High Risk, Medium Risk and Low Risk that take into account fundamental factors as well as liquidity and volatility of the stock. Please note that the risk rating may impact the level of total return that is required for specified recommendation.

The author has no conflict of interest with the company that is the subject of this document.

Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

Rating History - PBG

| Date | Recommendation | Target Price | Last Price (PLN) |
|------------|----------------|--------------|------------------|
| 17.02.2009 | BUY Low Risk | 220 | 187.9 |

IPOPEMA Research - Distribution by rating category (Jan 1 - Mar 31, 2009)

| | Number | % |
|------|--------|-----|
| Buy | 19 | 49% |
| Hold | 14 | 36% |
| Sell | 6 | 15% |